Original studyIncidence of Hypogammaglobulinemia in Patients Receiving Rituximab and the Use of Intravenous Immunoglobulin for Recurrent Infections
Introduction
Rituximab is a chimeric monoclonal antibody that binds to the CD20 antigen present on all peripheral B cells. In 1997, it became the first antibody approved for treatment of relapsed or refractory low-grade or follicular CD20+ B-cell non-Hodgkin lymphoma (NHL), based on clinical trials that evaluated its safety and efficacy in the early 1990s.1, 2, 3 Its use has subsequently widened to include treatment of all B-cell malignancies, including aggressive NHL and chronic lymphocytic leukemia.4, 5, 6, 7, 8, 9 The use of rituximab has also extended to nonmalignant indications, including rheumatoid arthritis.9
The efficacy of rituximab in these conditions as well as rituximab's favorable toxicity profile have led to several studies that evaluated rituximab as maintenance therapy after treatment for newly diagnosed or relapsed NHL. In addition, maintenance rituximab has been evaluated after high-dose therapy and autologous stem cell rescue in both indolent and aggressive lymphoma.10, 11, 12, 13, 14, 15, 16, 17
To date, 6 randomized trials have published results on the role of maintenance rituximab in indolent NHL and have noted improvements in progression-free survival. Maintenance therapy should ideally sustain prolonged remission, be well tolerated, and have minimal toxicities. Although rituximab meets these criteria and has contributed to extending periods of remission duration, the long-term impact of rituximab on B-cell depletion is not well understood. Long-term use may be associated with an increased incidence of grade 3 and 4 infections, neutropenia, hepatitis B reactivation, squamous cell skin carcinoma, and progressive multifocal leukoencephalopathy.18, 19, 20, 21 Furthermore, hypogammaglobulinemia associated with rituximab use has been documented in several settings: rituximab after high-dose therapy and autologous stem cell rescue, rituximab for autoimmune disorders in children with immunosuppression, and rituximab in patients with T-cell abnormalities.22, 23, 24, 25, 26, 27
To understand the relationship between the use of rituximab and the development of hypogammaglobulinemia, we undertook a retrospective study to evaluate serum immunoglobulins (SIgG) and rituximab. In addition, we examined if patients receiving rituximab developed symptomatic hypogammaglobulinemia that required treatment with intravenous immunoglobulin (IVIG).
Section snippets
Patients and Methods
This study was performed under a waiver of authorization from the institutional review board at Memorial Sloan-Kettering Cancer Center (MSKCC). We used DAVInCI (Data Analysis and Visualization for Integrated Cancer Information), a Web-based data mining tool, to identify patients with B-cell lymphoma who had been treated with rituximab either as a single agent for primary or maintenance therapy or in combination with chemotherapy as part of induction or salvage treatment at MSKCC between
Patient Characteristics
Two hundred eleven patients with NHL had serial quantitative immunoglobulin studies before and subsequent to therapy with rituximab, and were included in the analysis (Table 1). Eighty-two percent of patients (173/211) received rituximab as immunotherapy or chemoimmunotherapy for first-line treatment. Eighteen percent of patients (38/211) received rituximab for relapsed or refractory disease. The median age of patients was 58 years old (range, 9-90 years). The histologies included diffuse large
Discussion
In this data set, we observed that rituximab administration was associated with a high frequency of hypogammaglobulinemia. This occurred in concert with a moderate risk of symptomatic hypogammaglobulinemia that required use of IVIG, particularly among patients who received multiple courses of rituximab. In addition, we found that the number of doses of rituximab significantly correlated to the development of symptomatic hypogammaglobulinemia.
In this study, we examined the impact of rituximab on
Disclosure
A. Zelenetz has received research support from Genentech, Roche, and Biogen/IDEC; he has also performed consulting for Genentech and Roche. Genentech/Roche and Biogen/IDEC were not involved in this study. The remaining authors have stated that they have no conflicts of interest.
Acknowledgment
The authors thank Carol Pearce, MSKCC Department of Medicine writer/editor, for her editorial assistance.
References (37)
- et al.
IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
Blood
(1997) - et al.
Chop-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group
Lancet Oncol
(2006) - et al.
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
Lancet
(2010) - et al.
Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis
Ann Oncol
(2004) - et al.
Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study
Ann Oncol
(2004) - et al.
Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma
Blood
(2004) - et al.
Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma
Ann Oncol
(2009) - et al.
Three cases of activation of cutaneous squamous-cell carcinoma during treatment with prolonged administration of rituximab
Clin Oncol (R Coll Radiol)
(2006) - et al.
Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) Project
Lancet Oncol
(2009) - et al.
High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication
Ann Oncol
(2006)
Immunoglobulin therapy to control lung damage in patients with common variable immunodeficiency
Int Immunopharmacol
High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease
Lancet
Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients
J Pediatr
IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma
J Clin Oncol
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program
J Clin Oncol
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma
N Engl J Med
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte
J Clin Oncol
Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia
J Clin Oncol
Cited by (247)
Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: Pathogenesis, risk of infection, and disease management
2023, Multiple Sclerosis and Related DisordersHepatitis B Virus Reactivation in Patients Receiving Bruton Tyrosine Kinase Inhibitors
2023, Clinical Lymphoma, Myeloma and LeukemiaInfections in patients with chronic lymphocytic leukemia
2023, Hematology, Transfusion and Cell TherapyInfectious risk when prescribing rituximab in patients with hypogammaglobulinemia acquired in the setting of autoimmune diseases
2023, International ImmunopharmacologyHypogammaglobulinemia, late-onset neutropenia, and infections following rituximab
2023, Annals of Allergy, Asthma and Immunology